ペプチド治療の世界市場:産業分析・機会分析

◆英語タイトル:Peptide Therapeutics Market: Global Industry Analysis and Opportunity Assessment, 2015 - 2020
◆商品コード:FMI609103
◆発行会社(調査会社):Future Market Insights
◆発行日:2015年11月30日
◆ページ数:111
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆調査対象地域:グローバル
◆産業分野:医療
◆販売価格オプション(消費税別)
Individual (single user)USD5,000 ⇒換算¥570,000見積依頼/購入/質問フォーム
EnterpriseUSD10,000 ⇒換算¥1,140,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日~2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送いたしますので、請求書発行日より2ヶ月以内に銀行振込にて支払をお願いします。(支払期限と方法は調整可能、振込先:三菱東京UFJ銀行/京橋支店/H&Iグローバルリサーチ株式会社)
※レポート購入後、該当レポートに記載の英語表現や単語の意味に関しましては無料でお答えいたします。(但し、対応範囲は弊社で判断)
※上記の日本語題名はH&Iグローバルリサーチが翻訳したものです。英語版原本には日本語表記はありません。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はFuture Market Insights社の日本における正規販売代理店です。Future Market Insights社の概要及び新刊レポートはこちらでご確認いただけます。



※本調査レポートでは、ペプチド治療の世界市場について調査・分析し、市場概観、ペプチド治療の世界市場規模、市場規模予測、地域別分析(アメリカ、ヨーロッパ、アジア等)、セグメント別市場分析、競争状況、ペプチド治療市場動向、関連企業分析などを含め、以下の構成でお届けいたします。
【レポートの概要】

Future Market Insights offers a 6-year forecast of the global peptide therapeutics market between 2015 and 2020. In terms of value, the market is expected to register a CAGR of 2.9% during the forecast period. This study demonstrates market dynamics and trends in all seven regions that influence the current environment and future status of the peptide therapeutics market over the forecast period.
Report Description

This Future Market Insights report examines the peptide therapeutics market for the period 2015–2025. The primary objective of the report is to offer insights into developments in the peptide therapeutics market that are significantly transforming global businesses and enterprises.

The global peptide therapeutics market report begins with defining ‘what are peptides’ and the various drug classes using peptides with regard to various ailments. It is followed by an overview of the global peptide therapeutics market. The overview section includes FMI analysis of key trends, drivers, restraints, trends and opportunities that are influencing growth of the peptide therapeutics market. It also includes an insight into upcoming drug pipeline of various drug makers using peptides and market shares of major players, apart from region-specific regulations. Impact analyses of key growth drivers and restraints based on a weighted average model have been included in the ‘global peptide therapeutics market report’ to better equip customers and readers with region specific trends and insights.

The primary driving factors for peptide therapeutics are significant increase in cases of metabolic disorders such as diabetes, obesity, and osteoporosis. Further, increase in cancer incidences have also triggered the growth of the peptide therapeutics market. Research indicates that brain disorders including developmental, psychiatric and neurodegenerative diseases represent a significant disease burden in terms of human suffering and economic cost across the globe. These pump demand for peptide-based drugs for major ailments. The primary factor hampering growth of the peptide market is rising product complexity and lack of skilled labour to manufacture these drugs.

The global peptide therapeutics market is segmented based on disease indications. These include cancer. Respitaory, CNS, cardio-vascular, metabolic disorders and others. A detailed analysis has been provided for all ten categories of diseases and sub-segment in terms of market size, Y-o-Y growth rate, absolute $ opportunity and BPS analysis.

The report has also been segmented based on various drug administration channels such oral and parenteral. A deep analyses along with market attractiveness for each of the categories have been provided in the report

The next section of the report highlights the peptide therapeutics market by region. It provides a market outlook for 2014–2020 and sets the forecast within the context of the peptide therapeutics market. The study discusses key regional trends contributing to growth of the peptide therapeutics market worldwide, as well as analyses the extent to which drivers are influencing this market in each region. Key regions assessed in this report include North America, Europe, Asia Pacific and Rest of the world.

The above sections – by disease indication, route of administration and region – evaluate the present scenario and growth prospects of the peptide therapeutics market for the period 2014 –2020. We have considered 2014 as the base year and provide data for the forecast period, i.e. 2014–2020.

To ascertain the market size of peptide therapeutics, we have also considered revenue generated by drug manufacturers. The forecast presented here assesses the total revenue by value across the peptide therapeutics market. In order to offer an accurate forecast, we started by sizing the current market, which forms the basis of how the peptide therapeutics market is expected to develop in the future. Given the characteristics of the market, we triangulated the outcome of three different types of analysis, based on supply side, downstream industry demand and the economic envelope.

In addition, it is imperative to note that in an ever-fluctuating global economy, we not only conduct forecasts in terms of CAGR, but also analyse based on key parameters such as year-on-year (Y-o-Y) growth rates to understand the predictability of the market and to identify the right opportunities across the peptide therapeutics market.

The peptide therapeutics’ market segments in terms of disease indication, route of administration and region are analysed in terms of Basis Point Share (BPS) to understand individual segment’s relative contributions to market growth. This detailed level of information is important for identification of various key trends in the peptide therapeutics market.

Another key feature of this report is the analysis of key segments in terms of absolute dollar opportunity. This is traditionally overlooked while forecasting the market. However, absolute dollar opportunity is critical for assessing the level of opportunity that a provider can look to achieve, as well as to identify potential resources from a sales and delivery perspective of the peptide therapeutics market.

To understand key growth segments in terms of growth and adoption for the ten disease indications across the globe in the near future, Future Market Insights developed the peptide therapeutics market ‘Attractiveness Index’. The resulting index should help providers identify real market opportunities.

In the final section of the report on peptide therapeutics, ‘Competitive Landscape’ is included to provide report audiences with a dashboard view, based on categories of providers in the value chain of the peptide therapeutics product portfolio and key differentiators. Key categories of providers covered in the report are peptide therapeutics manufacturers. This section is primarily designed to provide clients with an objective and detailed comparative assessment of key providers specific to a market segment in the peptide therapeutics value chain and the potential players for the same. Report audiences can gain segment-specific vendor insights to identify and evaluate key competitors based on in-depth assessment of capabilities and successes in peptide therapeutics marketplace.

Detailed profiles of the drug makers are also included in the scope of the report to evaluate their long-term and short-term strategies, key offerings, SWOT analysis and recent developments. Key players include Amgen, Inc., AstraZeneca plc, Bachem Holding AG, Eli Lilly & Co., Ipsen, Lonza, Inc., Merck & Co., Novartis AG, Novo Nordisk A/S, Polypeptide Group, Roche Holding AG, Sanofi, Takeda Pharmaceutical Company Limited and Teva Pharmaceuticals Limited.

Key Segments Covered

Disease Indication
Cancer
CNS indications
Cardiovascular Diseases
Metabolic Diseases
Infections
Haematological disorders
Gastrointestinal Disorders
Respiratory Disorders
Acromegaly
Others (includes pain therapeutics, osteoporosis, etc.)
By Route of Drug Administration
Oral
Parenteral

Key Regions Covered

North America
Europe
Asia Pacific
Rest of World

Key Companies

Amgen, Inc.,
AstraZeneca plc,
Bachem Holding AG, Eli Lilly & Co.,
Ipsen,
Lonza, Inc.,
Merck & Co.,
Novartis AG,
Novo Nordisk A/S,
Polypeptide Group,
Roche Holding AG,
Sanofi,
Takeda Pharmaceutical Company Limited and
Teva Pharmaceuticals Limited

【レポートの目次】

Table Of Content

Chapter 1 Introduction

1.1 Report Description

1.2 Market Segmentation

1.3 Research Methodology

1.4 List of Abbreviations

1.5 Assumptions and Stipulations

Chapter 2 Executive Summary

2.1 Market Snapshot: Global Peptide Therapeutics Market (2014 & 2020)

2.2 Global Peptide Therapeutics Market, by Applications, 2014 (USD Million)

Chapter 3 Global Peptide Therapeutics Market Overview

3.1 Introduction

3.2 Emerging Trends in Peptide Therapeutics Market

3.2.1 Trends in Peptide Manufacturing Technology

3.2.2 Trends in Peptide API Supply

3.3 Market Dynamics

3.3.1 Drivers

3.3.1.1 Increase in cancer and diabetes patient population to propel the growth of new peptides

3.3.1.2 Rich R&D pipeline of peptide drugs is expected to drive growth

3.3.1.3 Technological advancements have reduced total production cost of peptides

3.3.2 Restraints

3.3.2.1 Increasing complexity of peptides is a huge challenge for API manufacturers

3.3.2.2 Lack of regulatory standards

3.3.3 Opportunities

3.3.3.1 Generic peptides market to flourish with patent cliff expected during the forecast period

3.3.3.2 Biotech firms collaborating with large pharmaceutical companies to explore further growth

3.4 Regulatory Scenario

3.5 Porter’s Five Forces Analysis: Global Peptide Therapeutics Market

3.5.1 Bargaining Power of Suppliers

3.5.2 Bargaining Power of Buyer

3.5.3 Threat of Substitutes

3.5.4 Threat of New Entrants

3.5.5 Competitive Rivalry

3.6 Event Impact Analysis

3.6.1 Event Impact Analysis: Global Peptide Therapeutics Market

3.7 Market Attractiveness Analysis

3.7.1 Market Attractiveness Analysis of Global Peptide Therapeutics Market, by Geography, 2014

3.8 Market Share Analysis

Chapter 4 Global Peptide Therapeutics Market, by Applications

4.1 Introduction

4.1.1 Global Peptide Therapeutics Market Revenue, by Application, 2014 – 2020 (USD Million)

4.2 Cancer

4.2.1 Global Cancer Peptide Therapeutics Market Revenue, 2014 – 2020 (USD Million)

4.2.2 Zoladex (goserelin)

4.2.3 Velcade (bortezomib)

4.2.4 Lupron/ Enantone/ Eligard (leuprorelin)

4.2.5 Others

4.3 Cardiovascular

4.3.1 Global Cardiovascular Disorders Peptide Therapeutics Market Revenue, 2014 – 2020 (USD Million)

4.3.2 Angiomax (bivalirudin)

4.3.3 Integrilin (eptifibatide)

4.4 Central Nervous System

4.4.1 Global Central Nervous System Peptide Therapeutics Market Revenue, 2014 – 2020 (USD Million)

4.4.2 Copaxone (glatiramer)

4.5 Metabolic Disorders

4.5.1 Global Metabolic Disorders Peptide Therapeutics Market Revenue, 2014 – 2020 (USD Million)

4.5.2 Victoza (liraglutide)

4.5.3 Byetta (exenatide)

4.5.4 Others

4.6 Infection

4.6.1 Global Infection Peptide Therapeutics Market Revenue, 2014 – 2020 (USD Million)

4.6.2 Incivek (telaprevir)

4.6.3 Victrelis (boceprevir)

4.7 Hematological Disorders

4.7.1 Global Hematological Disorders Peptide Therapeutics Market Revenue, 2014 – 2020 (USD Million)

4.7.2 Firazyr (icatibant)

4.7.3 Kalbitor (ecallantide)

4.8 Gastrointestinal Disorders

4.8.1 Global Gastrointestinal Disorders Peptide Therapeutics Market Revenue, 2014 – 2020 (USD Million)

4.8.2 Gattex (teduglutide)

4.8.3 Linzess (linaclotide)

4.9 Respiratory Disorders

4.9.1 Global Respiratory Disorders Peptide Therapeutics Market Revenue, 2014 – 2020 (USD Million)

4.10 Acromegaly

4.10.1 Global Acromegaly Peptide Therapeutics Market Revenue, 2014 – 2020 (USD Million)

4.11 Other Applications

4.11.1 Global Other Applications Peptide Therapeutics market Revenue, 2014 – 2020 (USD Million)

Chapter 5 Global Peptide Therapeutics Market, by Route of Administration

5.1 Introduction

5.1.1 Global Peptide Therapeutics Market Revenue, by Route of Administration, 2014 – 2020 (USD Million)

5.2 Parenteral Route of Administration

5.2.1 Global Peptide Therapeutics Market Revenue, by Parenteral Route of Administration, 2014 – 2020 (USD Million)

5.3 Oral Route of Administration

5.3.1 Global Peptide Therapeutics Market Revenue, by Oral Route of Administration, 2014 – 2020 (USD Million)

Chapter 6 Global Peptide Therapeutics Market, by Marketing Status

6.1 Introduction

6.1.1 Global Peptide Therapeutics Market Revenue, by Marketing Status, 2014 – 2020 (USD Million)

6.2 Branded Peptide Therapeutics

6.2.1 Global Branded Peptide Therapeutics Market Revenue, 2014 – 2020 (USD Million)

6.3 Generic Peptide Therapeutics

6.3.1 Global Generic Peptide Therapeutics Market Revenue, 2014 – 2020 (USD Million)

Chapter 7 Global Peptide Therapeutics Pipeline Overview

7.1 Introduction

7.1.1 Global Peptide Therapeutics Pipeline Overview

Chapter 8 Global Peptide Therapeutics Market, by Geography

8.1 Introduction

8.1.1 Global Peptide Therapeutics Market Revenue, by Geography, 2014 – 2020 (USD Million)

8.2 North America

8.2.1 North America Peptide Therapeutics Market Revenue, 2014 – 2020 (USD Million)

8.3 Europe

8.3.1 Europe Peptide Therapeutics Market Revenue, 2014 – 2020 (USD Million)

8.4 Asia Pacific

8.4.1 Asia Pacific Peptide Therapeutics Market Revenue, 2014 – 2020 (USD Million)

8.5 Rest of the World

8.5.1 Rest of the World Peptide Therapeutics Market Revenue, 2014 – 2020 (USD Million)

Chapter 9 Recommendations

9.1 Rigorous research and development (R&D) would yield new products

9.2 Facility expansion in emerging economies

9.3 Rapid inorganic growth through acquisitions

Chapter 10 Company Profiles

10.1 Amgen, Inc.

10.1.1 Company Overview

10.1.2 Financial Overview

10.1.3 Product Portfolio

10.1.4 Business Strategies

10.1.4.1 Mergers and acquisitions

10.1.5 Recent Developments

10.2 AstraZeneca plc

10.2.1 Company Overview

10.2.2 Financial Overview

10.2.3 Product Portfolio

10.2.4 Business Strategies

10.2.4.1 Acquisitions and collaborations

10.2.5 Recent Developments

10.3 Bachem Holding AG

10.3.1 Company Overview

10.3.2 Financial Overview

10.3.3 Product Portfolio

10.3.4 Business Strategies

10.3.4.1 Focus on profitable segments for market expansion and development

10.3.5 Recent Developments

10.4 CordenPharma International GmbH

10.4.1 Company Overview

10.4.2 Financial Overview

10.4.3 Product Portfolio

10.4.4 Business Strategies

10.4.4.1 Gaining competitive edge through compliance with regulatory authorities

10.4.4.2 Mergers and Acquisitions

10.4.5 Recent Developments

10.5 Eli Lilly and Company

10.5.1 Company Overview

10.5.2 Financial Overview

10.5.3 Product Portfolio

10.5.4 Business Strategies

10.5.4.1 Extensive R&D activities

10.5.4.2 Collaborations and agreements

10.5.5 Recent Developments

10.6 Ipsen S.A.

10.6.1 Company Overview

10.6.2 Financial Overview

10.6.3 Product Portfolio

10.6.4 Business Strategies

10.6.4.1 Mergers and Acquisitions

10.6.5 Recent Developments

10.7 Lonza Group Ltd.

10.7.1 Company Overview

10.7.2 Financial Overview

10.7.3 Product Portfolio

10.7.4 Business Strategies

10.7.4.1 Divestiture Strategies

10.7.4.2 Strategic Agreements

10.7.5 Recent Developments

10.8 Merck & Co., Inc.

10.8.1 Company Overview

10.8.2 Financial Overview

10.8.3 Product Portfolio

10.8.4 Business Strategies

10.8.4.1 Mergers and acquisitions

10.8.4.2 Strategic collaborations

10.8.4.3 Expansion in emerging markets

10.8.5 Recent Developments

10.9 Novartis AG

10.9.1 Company Overview

10.9.2 Financial Overview

10.9.3 Product Portfolio

10.9.4 Business Strategies

10.9.4.1 Product pipeline expansion

10.9.5 Recent Developments

10.10 Novo Nordisk A/S

10.10.1 Company Overview

10.10.2 Financial Overview

10.10.3 Product Portfolio

10.10.4 Business Strategies

10.10.4.1 Dominance in diabetes portfolio

10.10.5 Recent Developments

10.11 PolyPeptide Group

10.11.1 Company Overview

10.11.2 Financial Overview

10.11.3 Product Portfolio

10.11.4 Business Strategies

10.11.5 Recent Developments

10.12 Roche Holdings AG

10.12.1 Company Overview

10.12.2 Financial Overview

10.12.3 Product Portfolio

10.12.4 Business Strategies

10.12.4.1 Consistent product launches

10.12.4.2 Mergers and Acquisitions

10.12.5 Recent Developments

10.13 Sanofi

10.13.1 Company Overview

10.13.2 Financial Overview

10.13.3 Product Portfolio

10.13.4 Business Strategies

10.13.4.1 Collaborations

10.13.5 Recent Developments

10.14 Takeda Pharmaceutical Company Limited

10.14.1 Company Overview

10.14.2 Financial Overview

10.14.3 Product Portfolio

10.14.4 Business Strategies

10.14.4.1 Growth in emerging markets

10.14.4.2 Strategic collaborations and agreements

10.14.5 Recent Developments

10.15 Teva Pharmaceutical Industries Ltd.

10.15.1 Company Overview

10.15.2 Financial Overview

10.15.3 Product Portfolio

10.15.4 Business Strategies

10.15.4.1 Strengthening foundation and driving organic growth

10.15.4.2 Focusing on Copaxone and other key specialty products

1.1 10.15.5 Recent Developments
List of Tables

TABLE 1 Market Snapshot: Global Peptide Therapeutics Market (2014 & 2020)

TABLE 2 Event Impact Analysis: Global Peptide Therapeutics Market

TABLE 3 Global Peptide Therapeutics Market Revenue, by Application, 2014 – 2020 (USD Million)

TABLE 4 Global Cancer Peptide Therapeutics Market Revenue, 2014 – 2020 (USD Million)

TABLE 5 Global Cardiovascular Disorders Peptide Therapeutics Market Revenue, 2014 – 2020 (USD Million)

TABLE 6 Global Metabolic Disorders Peptide Therapeutics Market Revenue, 2014 – 2020 (USD Million)

TABLE 7 Global Infection Disorders Peptide Therapeutics Market Revenue, 2014 – 2020 (USD Million)

TABLE 8 Global Hematological Disorders Peptide Therapeutics Market Revenue, 2014 – 2020 (USD Million)

TABLE 9 Global Gastrointestinal Disorders Peptide Therapeutics Market Revenue, 2014 – 2020 (USD Million)

TABLE 10 Global Acromegaly Peptide Therapeutics Market Revenue, 2014 – 2020 (USD Million)

TABLE 11 Global Peptide Therapeutics Market Revenue, by Route of Administration, 2014 – 2020 (USD Million)

TABLE 12 Global Peptide Therapeutics Market Revenue, by Marketing Status, 2014 – 2020 (USD Million)

TABLE 13 Global Peptide Therapeutics Market Pipeline Overview

TABLE 14 Global Peptide Therapeutics Market Revenue, by Geography, 2014 – 2020 (USD Million)
List of Figures

FIG. 1 Peptide Therapeutics Market Segmentation

FIG. 2 Global Peptide Therapeutics Market, by Applications, 2014 (USD Million)

FIG. 3 Porter’s Five Forces Analysis: Global Peptide Therapeutics Market

FIG. 4 PEST Analysis North America and Europe

FIG. 5 Market Attractiveness Analysis of Global Peptide Therapeutics Market, by Geography, 2014

FIG. 6 Market Share Analysis of Global Peptide Therapeutics Market, by Key Players, 2014 (Value %)

FIG. 7 Global Central Nervous System Peptide Therapeutics Market Revenue, 2014 – 2020 (USD Million)

FIG. 8 Global Respiratory Disorders Peptide Therapeutics Market Revenue, 2014 – 2020 (USD Million)

FIG. 9 Global Other Applications Peptide Therapeutics Market Revenue, 2014 – 2020 (USD Million)

FIG. 10 Global Peptide Therapeutics Market Revenue, by Parenteral Route of Administration, 2014 – 2020 (USD Million)

FIG. 11 Global Peptide Therapeutics Market Revenue, by Oral Route of Administration, 2014 – 2020 (USD Million)

FIG. 12 Global Branded Peptide Therapeutics Market Revenue, 2014 – 2020 (USD Million)

FIG. 13 Global Generic Peptide Therapeutics Market Revenue, 2014 – 2020 (USD Million)

FIG. 14 North America Peptide Therapeutics Market Revenue, 2014 – 2020 (USD Million)

FIG. 15 Europe Peptide Therapeutics Market Revenue, 2014 – 2020 (USD Million)

FIG. 16 Asia Pacific Peptide Therapeutics Market Revenue, 2014 – 2020 (USD Million)

FIG. 17 Rest of the World Peptide Therapeutics Market Revenue, 2014 – 2020 (USD Million)

FIG. 18 Amgen, Inc: Annual Revenue, 2014 – 2014 (USD Million)

FIG. 19 AstraZeneca plc: Annual Revenue, 2014 – 2014 (USD Million)

FIG. 20 Bachem Holding AG: Annual Revenue, 2014 – 2014 (USD Million)

FIG. 21 Eli Lilly and Company: Annual Revenue, 2014 – 2014 (USD Million)

FIG. 22 Ipsen S.A.: Annual Revenue, 2014 – 2014 (USD Million)

FIG. 23 Lonza Group Ltd.: Annual Revenue, 2014 – 2014 (USD Million)

FIG. 24 Merck & Co., Inc.: Annual Revenue, 2014 – 2014 (USD Million)

FIG. 25 Novartis AG Annual Revenue: 2014 – 2014 (USD Million)

FIG. 26 Novo Nordisk A/S Annual Revenue: 2014 – 2014 (USD Million)

FIG. 27 Roche Holdings AG: Annual Revenue: 2014 – 2014 (USD Million)

FIG. 28 Sanofi: Annual Revenue, 2014 – 2014 (USD Million)

FIG. 29 Takeda Pharmaceutical Co. Ltd.: Annual Revenue: 2014 – 2014 (USD Million)

FIG. 30 Teva Pharmaceutical Co. Ltd.: Annual Revenue: 2014 – 2014 (USD Million)



【レポートのキーワード】

ペプチド治療

【免責事項】
※当レポート上の情報/データは調査会社が信頼できると判断した情報源から入手したものに基づき作成しましたが、その正確性・完全性を保証するものではありません。当レポートに記載された情報/データ/見解/仮説などは作成時点又は発行時点における調査会社の判断であり、その後の状況変化に応じて変更される場合があります。当レポート上の情報/データに基づいたお客様の意思決定又は実行による結果について、調査会社/発行会社/販売会社H&Iグローバルリサーチ(株)はその責を負いかねますのでご了承ください。英文資料の紹介ページにおける日本語題名/概要/目次はH&Iグローバルリサーチ(株)が翻訳した内容であり、翻訳の正確性・完全性を保証するものではありません。

★調査レポート[ペプチド治療の世界市場:産業分析・機会分析]についてメールでお問い合わせはこちら


※世界の市場調査資料 総合販売サイトMarketReport.jpはH&Iグローバルリサーチ株式会社が運営しております。海外進出、グローバル事業戦略策定、新規事業機会の発掘、競合他社の動向把握などに必要な情報やインサイトをお客様にご提供しております。H&Iグローバルリサーチ(登録第5864124号)及びH&I(登録第5783645号)はH&Iグローバルリサーチ株式会社の商標です。
※当サイトでは2016年12月08日現在 219,203 件の調査レポートを取り扱っております。当サイトに掲載していない調査資料も弊社を通してご購入可能ですので、お気軽にご連絡ください。ウェブサイトでは紹介しきれない資料も数多くございます。

◆H&Iグローバルリサーチのお客様(例)◆